Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 25;91(S-5):13-22.
doi: 10.23750/abm.v91iS-5.9911.

Treatment of very high-risk classical Hodgkin Lymphoma: cases' selection from real life and critical review of the literature

Chiara Rusconi  1 , Sabino Ciavarella  2 , Alberto Fabbri  3 , Leonardo Flenghi  4 , Benedetta Puccini  5 , Alessandro Re  6 , Marco Sorio  7 , Anna Vanazzi  8 , Manuela Zanni  9
Affiliations
Review

Treatment of very high-risk classical Hodgkin Lymphoma: cases' selection from real life and critical review of the literature

Chiara Rusconi et al. Acta Biomed. .

Abstract

Over the last 4 decades, advances in radiation therapy and the addition of combination chemotherapy have significantly increased the cure rate of patients with HL, with a 5-year OS of about 90% . However, despite high rate of cure after first line of therapy, 5%-10% of HLs are refractory to the treatment, and 10-30% of patients have a disease relapse after a complete response (CR). Relapsed HL can be treated with salvage therapies with a long-lasting complete remission in 80% of cases. In recent years, novel drugs are available for the patients with relapsed/refractory HL, like Brentuximab Vedotin and immune checkpoint inhibitors. These drugs have been able to rescue a cohort of patients who subsequently could receive an allogeneic stem-cell transplant. Our cases have been chosen because they are representative of critical issues in the management of relapsed/refractory HL; our experiences are consistent with what reported by other Authors.

PubMed Disclaimer

Conflict of interest statement

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

    1. Eichenauer DA, Aleman BPM, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018;29(Supplement 4):iv19–iv29. - PubMed
    1. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–15. - PubMed
    1. Carella AM, Corradini P, Mussetti A, et al. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Annals of Hematology. 2018;97:1301–15. - PubMed
    1. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability forcure. J Clin Oncol. 1992;10:210–8. - PubMed
    1. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM) Ann Oncol. 1998;9(3):289–95. - PubMed